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Abstract 
Background: Local implantation of ex vivo concentrated, washed and filtrated human bone marrow-derived 
mononuclear cells (BMC) seeded onto β-tricalciumphosphate (TCP) significantly enhanced bone healing in a preclini-
cal segmental defect model. Based on these results, we evaluated in a first clinical phase-I trial safety and feasibility 
of augmentation with preoperatively isolated autologous BMC seeded onto β-TCP in combination with angle stable 
plate fixation for the therapy of proximal humeral fractures as a potential alternative to autologous bone graft from 
the iliac crest.
Methods: 10 patients were enrolled to assess whether cell therapy with 1.3 × 106 autologous BMC/ml/ml β-TCP, 
collected on the day preceding the definitive surgery, is safe and feasible when seeded onto β-TCP in patients with a 
proximal humeral fracture. 5 follow-up visits for clinical and radiological controls up to 12 weeks were performed.
Results: β-tricalciumphosphate fortification with BMC was feasible and safe; specifically, neither morbidity at the 
harvest site nor at the surgical wound site were observed. Neither local nor systemic inflammation was noted. All 
fractures healed within the observation time without secondary dislocation. Three adverse events were reported: 
one case each of abdominal wall shingles, tendon loosening and initial screw perforation, none of which presumed 
related to the IND.
Conclusions: Cell therapy with autologous BMC for bone regeneration appeared to be safe and feasible with no 
drug-related adverse reactions being described to date. The impression of efficacy was given, although the study was 
not powered nor controlled to detect such. A clinical trial phase-II will be forthcoming in order to formally test the 
clinical benefit of BMC-laden β-TCP for PHF patients.
Trial registration The study was registered in the European Clinical Trial Register as EudraCT No. 2012-004037-17. Date 
of registration 30th of August 2012. Informed consent was signed from all patients enrolled.
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Background
Large bone defects after severe trauma, debridement of 
pseudarthrosis and osteomyelitis, or osteoporotic frac-
tures remain a major challenge in trauma and orthopedic 
surgery due to impaired vascularization and delayed 
bone healing. Current treatment protocols recommend 
the use of autologous and allogenous bone to repair 
these defects but are fraught with high donor site mor-
bidity, reduced biological capacity, limited availability of 
autologous bone, immunogenicity or loosening of allo-
plastic implants and extended surgical times [1]. Tissue 
engineering is an attractive alternative approach to cur-
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minimize or eliminate the limitations and/or costly com-
plications of the latter.
Bone tissue engineering combines cells with regenerative 
potential, synthetic or natural osteoconductive scaffolds 
(e.g. β-tricalciumphosphate, β-TCP) and biological factors 
[2, 3]. Previously, we demonstrated that cell based therapy 
using extensively cultivated stem cells (mesenchymal stem 
cells, MSC, endothelial progenitor cells, EPC) implanted on 
a β-TCP scaffold into a femoral large-sized segmental bone 
defect in rats leads to improved vascularization and new 
bone formation in the defect site [4–6]. Albeit efficient, the 
use of long-term cultured progenitor cells is fraught with 
disadvantages like delay of definitive surgery, questions of 
biological safety, high costs and is not yet established clini-
cally. Tissue engineering approaches using fresh autologous 
bone marrow mononuclear cells (BMC) might circumvent 
many of those limitations. Human BMC can be harvested 
and reintroduced to the patient within hours which is more 
compatible with the clinical requirement for rapid definitive 
fracture fixation. BMCs are already used in cardiology as 
well as in vascular surgery and are ideally suited for regen-
erative medicine due to their apparent regenerative poten-
tial and safety profile [7, 8]. Using a femur defect model in 
rats we previously demonstrated that BMCs combined with 
a β-TCP scaffold enhanced the bone healing response. The 
histological quality and the mechanical strength of femur 
defects treated with BMC were qualitatively comparable to 
those defects receiving cultured MSC and EPC [9].
Based on those promising results, we aimed to establish 
a cell-based bone regeneration procedure applicable in 
the whole field of bone defects after trauma, tumors, joint 
arthroplasty and in osteoporotic defects. We hypoth-
esized that transplantation of BMC + β-TCP into a large 
bone defect should be safe, feasible and should promote 
bone formation and bony bridging of the defect resulting 
in improved clinical outcomes.
Therefore, we investigated safety and feasibility of aug-
mentation with preoperatively isolated autologous BMC 
cells seeded onto β-TCP in combination with angle sta-
ble fixation (Philos plate®) for the therapy of proximal 
humeral fractures (PHF) in a clinical phase-I trial. This 
frequent fracture type is characterized by a high rate of 
secondary dislocation (varus collapse of the humeral 
head of more than 20° or screw perforation) and compli-
cation rate up to 30% [10]. Thus, this fracture is suitable 
to study in a standardized clinical situation bone healing 
by autologous bone marrow cell transplantation seeded 
onto an established scaffold.
Patients and methods
Objectives
This was a clinical phase-I trial to test safety and fea-
sibility of augmentation with preoperatively isolated 
autologous BMC cells seeded onto β-TCP in combination 
with angle stable fixation (Philos plate®) for the therapy 
of proximal humerus fractures.
Ethics and regulatory affairs
A manufacturing license for tissue procurement acc. 
to §20b German Medicines Law and for manufactur-
ing of the advanced therapy medicinal product (ATMP) 
“BMC2012” (see below) acc. to §13 German Medicines 
Law, the autologous cell-based study drug, was obtained 
from the local regulatory agency (Regierungspräsidium 
Darmstadt). Protocols for a German Medicines Law GCP 
trial were prepared and permissions from the local Eth-
ics board [No. 350/12] and the federal autority (PEI) [No. 
1769] were obtained for treatment of 10 consecutive, eli-
gible, consenting patients. The study was registered in the 
European Clinical Trial Register as EudraCT No. 2012-
004037-17. Informed consent was signed by all partici-
pants. No study-specific X-rays were performed.
Inclusion/exclusion criteria
Criteria for inclusion were 2-, 3- or 4-fragment fracture 
(Neer classification), dislocation of  ≥10  mm between 
fragments and/or angle of  ≥45° between fragments 
and/or dislocation of tuberculum major of  ≥5  mm, 
age  >18  years, informed consent for surgery and study 
participation.
Exclusion criteria were pregnancy, luxation fracture, 
nerve damage, progressive tumor disease and mental-
health problems or other causes for inability to provide 
informed consent.
Experimental group/control group
This was a single-arm uncontrolled study. All patients 
received cell-based therapy with BMC: open reduc-
tion internal fixation (ORIF) of the fracture, augmenta-
tion with composite of an acellular bone graft substitute 
(ß-TCP) and 1.3  ×  106 BMC/ml TCP. Epidemiological 
data of patients are shown in Table 1.
Investigational new drug (IND): BMC2012
Collection, manufacture, testing and release of the cell 
product BMC
On the day prior to surgery, 50 ml bone marrow, anti-
coagulated with heparin, were aseptically aspirated 
from the posterior iliac crest under local anesthesia in 
regulator-approved intervention rooms. Additionally, 
27  ml peripheral blood were aseptically collected into 
endotoxin-free “no additive” vials. Bone marrow aspi-
rate and blood were transported immediately under 
standardized conditions (20 ± 2 °C) to the Department 
of Transfusion Medicine and DRK Blutspendedienst, 
Frankfurt. The blood samples in the serum vacuettes 
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remained with the bone marrow aspirate at all times 
and were used to prepare autologous serum under GMP 
conditions. For this purpose clotted blood was centri-
fuged at 2800g for 15  min. The serum was aseptically 
aspirated (clean room class A in B) and used for final 
drug preparation.
BMC preparation was performed under full GMP in 
the certified facility of the Department of Transfusion 
Medicine as described in [11]. Briefly, BM aspirate was 
diluted in saline and subjected to Ficoll (Lonza, Verviers, 
Belgium) density purification. The interphase cells were 
carefully collected, pooled, washed and re-suspended in 
ex vivo (Lonza) containing 20% v/v autologous serum. All 
open and semi-open steps were performed in a class A 
in B, all other steps in a class B environment. BMC were 
counted, diluted to a final concentration of 1.3 × 10E6/
ml suspension media and aseptically transferred to a 
cryostorage bag (Miltenyi Biotech, Bergisch-Gladbach, 
Germany). The final product consisted of 12 ml BMC sus-
pension; it was stored at room temperature until use. The 
IND specification was as following: WBC concentration 
1.3 × 10e6 ± 10%/ml, CD34 + cell concentration meas-
ured and declared, CD45+ cell viability >95%, bioburden 
negative-to-date, donor negative by serology for Hepati-
tis A, B, C, Syphilis and HiV. Tests were performed using 
the following assays: Total leukocytes (WBC) were enu-
merated using the Sysmex XT1800 hemacytometer (Nor-
derstedt, Germany). Content of putative progenitor cells 
(CD271+/CD73+/CD45− (putative MSC); CD45+/
CD34+/CD133+/VEGFR2+  (putative EPC); CD45+ /
CD34+ /CD133+  (putative HSPC) was determined by 
single-platform flow cytometry using Trucount count-
ing beads (Becton–Dickinson, Heidelberg, Germany) 
and a dual-laser FACS Calibur (Becton–Dickinson). A 
sample for bioburden assessment was taken by overfill-
ing the final product bag by one mL and withdrawing one 
mL half of which was subsequently inoculated each onto 
aerobic and anaerobic BacT/Alert bottles (BioMerieux, 
Nürtingen, Germany [12].
HSCs were recognized following the ISHAGE con-
vention, as also laid out in the Eur. Pharm., as 7AAD-
negative, CD34+ /CD45dim/SSC-lo/FSC-lomid events 
(PANEL 1, not shown), using an IVD-grade commer-
cial HSC enumeration platform, SCE (BD, Heidelberg, 
Germany) [13]. The ISHAGE panel was subsequently 
extended to contain antibodies against CD133 and KDR 
for recognition of putative EPCs among the ISHAGE-
HSCs, and against CD73 and CD271 for recognition of 
putative MSCs among the CD45-negative cells (PANEL 
2, see Fig.  1). HSC enumeration was validated against 
the SCE kit (HSC frequency among CD45+  to within 
10% of each other throughout the relevant frequency 
range), in order to allow calculation of EPC and MSC 
concentrations based on HSC concentration in PANEL 
1 and relative frequency of EPC and MSC vs. HSC in 
PANEL 2.
Quality control further included assessment of vital-
ity (7AAD). All release-critical assays used were vali-
dated according to guidelines laid out in the European 
Pharmacopoiea.
Ancillary tests on the IND
Assessment of maximum storage time
With permission of the ethics committee, residual cell 
suspension not needed for formulation of the study drug 
was used for further analyses. Thus five (four for CFU-
F) residual patient samples were analysed over time to 
assess the shelf-life of the BMCs under the clinically rel-
evant storage conditions (X-Vivo10 w/20% autologous 
serum, room temperature, not gas-permeable storage 
bag).Flow cytometry was applied to determine altera-
tions of the frequencies of some putative progenitor cell 
populations (putative MSC, HSPC; CD45+/CD34+/
CD133±) over time (24, 48 and 72 h after BMC isolation) 
as described in [14].
Colony-forming units-fibroblast (CFU-F) were enu-
merated determined using the CFU-F-assay as described 
in [14].
Estimation of the seeding efficacy
The single step procedure for BMC seeding on β-TCP 
scaffold material mimicking the clinical intraoperative 
procedure was applied. Residual BMC from study partici-
pants [1.33 × 106 BMC/ml medium, n = 5] were dripped 
onto densely packed β-TCP scaffold material (granule 
size 1.4–2.8, 1.4–2.8  mm, Chronos, Synthes) in a cell 
strainer with 100 µm pore size (BD-Biosciences, Heidel-
berg, Germany). Non-adhering cells were collected at the 
bottom of the test tube, counted and the seeding efficacy 
was calculated.
Table 1 Patient epidemiology
Patient Age Gender Smoker Osteoporosis
1 69 Female No No
2 71 Female No No
3 69 Female Yes Yes
4 67 Female No No
5 64 Female No No
6 72 Male No No
7 76 Female No No
8 66 Female No No
9 71 Female No No
10 66 Female No No
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Application of the IND
Within 24  h of marrow aspiration, BMC were applied 
during surgery and plate osteosynthesis of the fractures. 
Briefly, the large bone defect was bridged following the 
clinical standard. Subsequently, the defect was filled with 
a clinically established β-TCP scaffold (size: 1.4–2.8 mm, 
Chronos, Synthes, Dubendorf, Switzerland), and an equal 
volume of BMC suspension was loaded carefully in  situ 
on the implanted β-TCP using a syringe. The phenotype 
of BMC adhering to the scaffold was analyzed previously 
[14].
Follow‑up per patient
Each study participant underwent five visits for study 
purposes and monitoring of safety/tolerability and bone 
healing over a period of 12  ±  2  weeks as depicted in 
Table 2.
Endpoints
Primary endpoints were safety and feasibility. To objec-
tively assess these, morbidity of cell harvesting proce-
dure, the occurrence of local infection at the fracture 
site after cell transplantation (inflammation, wound 
Fig. 1 HSCs were recognized as 7AAD-negative, CD34+ /CD45dim/SSC-lo/FSC-lomid events. (PANEL 1, not shown) using an IVD-grade commercial 
HSC enumeration platform, SCE (BD, Heidelberg, Germany). The ISHAGE panel was subsequently extended to contain antibodies against CD133 and 
KDR for recognition of putative EPCs among the ISHAGE-HSCs, and against CD73 and CD271 for recognition of putative MSCs among the CD45-
negative cells (PANEL 2, shown here)
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healing disruption) as well as systemic inflammation 
(WBC, CRP, IL-6, PCT) and fever (>38.5  °C) for more 
than 2  days were documented during the follow up 
period.
With regard to feasibility of the procedure of bone mar-
row harvesting, logistics for BMC preparation and trans-
port as well as explanatory power of the clinical controls 
relating to the possible clinical benefit were evaluated.
As secondary endpoints bone healing (X-ray), clinical 
functional outcome (DASH score), evaluation of medica-
tion and AEs were assessed.
Evaluation of bone healing
The “true anterior-posterior (true a.p.)” and “outlet-
view” X-rays of the shoulder were performed at Visit 1–5 
according to clinical standard in order to evaluate frac-
ture site and implant position as well as to detect screw-
cutting-out, osteonecrosis, pseudarthrosis and loosening 
of implants and definitive bone healing. Due to fracture-
immanent possible secondary varus dislocation we meas-
ured head-shaft-angle in true a.p. X-ray. Therefore, a line 
from the upper to the lower limit of joint surface was 
drawn (A–B line), then a perpendicular line to A–B line 
through the center of the humeral head (C–D line). The 
angle alpha between this line and the bisecting line of the 
humeral shaft (E–F line) was measured as head-shaft-
angle (Fig. 2).
Secondary dislocation was defined as a secondary loss 
of reposition result of  ≥20° of head-shaft-angle in the 
true a.p.
In order to detect a secondary screw-cutting-out we 
also measured the distance between the top of the screws 
to the joint surface (d).
DASH score
Twelve weeks postoperatively movement and function 
of the shoulder were evaluated by disabilities of the arm, 
shoulder and hand score (DASH) [15].
Therefore patients had to respond to thirty ques-
tions of a questionnaire about everyday function of the 
shoulder within the last week. Then the DASH-Score 
was measured. The DASH score gives evidence to func-
tion, symptoms and special activity (athlete, musician). 
A DASH-score of 0 is a result with an optimal function 
without limitation. A DASH score of 100 means a maxi-
mal limitation.
Evaluation of medication and AEs
Medication and AEs were documented at each study visit 
(V1–5) in descriptive manner.
Statistics
In this phase-I clinical trial safety and feasibility of 
cell based therapy by implanted bone marrow-derived 
mononuclear cells (BMC) for bone augmentation 
of plate-stabilized proximal humeral fractures were 
tested. Ten patients were planned and included in the 
study, all of whom received BMC 2012. Data were pre-
sented descriptively. Thus no statistical comparison 
was performed regarding neither data of safety and fea-
sibility nor data of secondary endpoints (bone healing, 
DASH score).
Data for cell experiments are evaluated statisti-
cally by non parametric Wilcoxon matched pair 
analysis, a p value below 0.05 indicates statistical 
significance. Results were presented either as box 
plots of the median (box: median, 25% quartile and 
Table 2 Patient flow chart of the clinical trial
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Timepoint 24 h before surgery, 
study inclusion, BMC 




1–7 days after surgery Within 6 ± 1 weeks 
after surgery
Within 12 ± 2 weeks 
after surgery
BM aspiration ×
Implantation of BMC ×
Inflammation (local) × × × × ×
Inflammation (WBC, 
CRP, IL-6, PCT) fever
× × × × ×
Evaluation of AEs × × × ×
Evaluation of medica-
tion
× × × × ×
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75% quartile; whiskers: minimum, maximum) or 
in text, respectively tables as median (25% quar-
tile/75% quartile).
Results
We generated formal study protocols, including IMPD, 
and applied for §40 AMG permission from the PEI for 
this phase I trial (EudraCT-Nr.:2012-004037-17, Date of 
registration: 30th of August 2012; Date enrolled first par-
ticipant: 11th of September 2013).
After regulatory approval 10 patients were recruited 
and completed follow-up between September 2013 and 
2014. Epidemiological information of patients is shown 
in Table 1.
Primary endpoints
For the endpoint safety/feasibility, morbidity from bone 
marrow aspiration, local infection at BM aspiration 
or surgery site, systemic inflammation and fever were 
investigated.
No side effects of bone marrow aspiration were seen. 
Even though suffering from a humeral fracture, bone 
marrow aspiration under local anesthesia was well 
tolerated by all patients. Furthermore, neither local 
inflammation nor disruption of wound healing process 
as signs of local infection were observed at any time. 
Regarding the blood parameters that might indicate 
systemic inflammation, CRP, IL-6, PCT and WBC were 
measured at all five visits. The expected initial increase 
of CRP- and IL-6-values after surgery was observed and 
subsequently decreased to normal homeostatic values 
after 1  week. Further, no systemic inflammation was 
diagnosed by measurement of procalcitonin (Fig. 3a–d). 
During the whole time no fever was reported.
With respect to feasibility, bone marrow harvesting, 
manufacturing within the narrow time slot and transport 
logistics were checked.
Bone marrow aspiration was feasible and well tolerated 
by all patients. Also the overall logistical implementation 
of bone marrow aspiration, transportation, production 
and final application of BMC during surgery and plate 
osteosynthesis of the fractures was well realizable within 
the short approved shelf life of the study drug.
Secondary endpoints
The secondary endpoints were bone healing assessed 
by X-ray, clinical functional outcome by means of the 
DASH-score, evaluation of medication and AEs.
In all 10 cases bone fracture healed within the observa-
tion time of 12 weeks (Fig. 4). During this period no sec-
ondary dislocations of the proximal subcapital humerus 
fracture were detected by radiological assessment of the 
head-shaft-angle (140.4° ±  2.6). In addition, no second-
ary screw perforation due to collapse of the humeral head 
or the osteosynthesis was noted on the X-ray images.
During study visits only three adverse events were 
reported. One patient each showed single-segment 
abdominal wall shingles, partial loosening of the tendon 
of the supraspinatus muscle and a surgical complication 
of an initial screw perforation. Solely in one case hospi-
talization was necessary in order to surgically reattach a 
supraspinatus tendon, which was consequently classified 
as a serious adverse event, albeit presumably not related 
to study drug, which was applied in the subcapital meta-
physeal area and not the tendon attachment site.
The clinical functional outcome by evaluation of the 
DASH-score after 12 weeks resulted in a value of 52 ± 7.9 
(mean ± SEM). It should be noted that the DASH-score 
is not only influenced by bone healing, but also by carti-
lage lesions or tendon issues, which are often observed in 
this age group [16].
Loss of CFU‑F frequency and reduction of BMC viability 
after 48 h
The viability of mononucleated cells, the frequency of 
putative hematopoietic stem cells (CD45+ CD34+ 
Fig. 2 Radiological assessment of humeral position after surgical 
repositioning and during convalescence: A line from the upper to the 
lower limit of joint surface (A–B line), and a perpendicular line to A–B 
were drawn through the center of the humeral head (C–D line). The 
angle alpha between this line and the bisecting line of the humeral 
shaft (E–F line) was called head-shaft-angle. The distance between the 
screw top and the joint surface (d) was also measured
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CD133+; CD45+ CD34+ CD133−) as well as of putative 
marrow stromal cells (CD45dimCD271+) were assessed by 
means of flow cytometry or CFU-F assay (marrow stromal 
cells) at 24  h (transplantation), 48, and 72  h after bone 
marrow aspiration (Table 3; Fig. 5). Viability declined sig-
nificantly from 24 to 48 and 72 h (p < 0.05, Table 4). Cor-
respondingly, the number of viable BMC being calculated 
in relation to the 24  h-values dropped significantly from 
24 to 72 h (p < 0.05, Table 4). In contrast, the frequencies 
of putative hematopoietic stem cells as well as of putative 
marrow stromal cells remained constant during the whole 
observation period, indicating equal sensitivity to storage 
lesion of all cellular subsets. No significant differences were 
seen between all time points. This result indicates that the 
absolute number of stem cells dropped consistently with 
the absolute BMC numbers (otherwise an enrichment or 
decline of stem cell frequency would have been seen). 
In contrast, absolute values of CFU-F frequency 
declined in trend from 24 to 48 h (p = 0.1) and signifi-
cantly from 24 to 72 h (p < 0.05). If CFU-F concentration 
is calculated as percent change to 24  h-values a signifi-
cant decline was seen between 24 and 48  h (p  <  0.05) 
respectively 24 and 72 h (p < 0.05, Table 4).
Estimation of seeding efficacy
The mean seeding efficacy was 59% ± 8.5 (mean ± SEM) 
applying a single step seeding procedure mimicking the 
situation in situ as described in the materials and meth-
ods section.
Discussion
We analyzed the safety and feasibility of autologous BMC 
in a clinical phase-I trial as a therapeutic option for the 
treatment of bone defects at high risk of secondary dislo-
cation in ten patients with a proximal humerus fracture. 
Both aspects, safety and feasibility, could be unequivo-
cally demonstrated. A near-identical BMC produc-
tion process is already approved by the German federal 
regulatory authority (Paul-Ehrlich-Institute, Germany) 
and established at the German Red Cross-Blood Ser-
vice (DRK-BSD, Frankfurt) for the application of BMC 
in acute myocardial infarction and limb ischemia [7, 8]. 
Albeit applied by a different route (i.e.) and for an entirely 
different clinical indication, in at least six cardiovascular 
clinical trials the drug was found to be safe and probably 
efficacious, as well as the logistics of re-applying the cells 
within 48 h of marrow collections were shown to be fea-
sible on a routine basis [11, 17–22]. The novelty of our 
approach dictates that similar reports about safety and 
feasibility of purified BMC for the treatment of bone 
defects are not yet available.
However, other treatment options ultimately based on 
the transplantation of vital bone derived cells respectively 
bone material within the operative procedure by direct 
separation were previously evaluated by other groups 
[23, 24]. It needs to be noted, that the large majority of 
Fig. 3 a–d Blood parameters of systemic inflammation, C-reactive 
protein (CRP), interleucin-6 (IL-6), procalcitonin (PCT) and white blood 
cells (WBC) were measured at every five visits (V1–5). The expected 
initial increase of CRP- and IL-6-values after surgery was observed; 
values subsequently decreased to within the normal range beyond 
week 1. Box plots of the median (box: median, 25% quartile and 75% 
quartile; whiskers: minimum, maximum)
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patients still receive complete cancellous bone graft 
from iliac crest or femur [25], which has the disadvan-
tage of donor site morbidity and limited material. Other 
approaches such as the use of nonviable scaffolds [26] 
cannot demonstrate a sufficient biological activity and 
guided bone healing. Thus, the advantages of using mini-
mally manipulated cell drugs as opposed to ex vivo cul-
tivated stem cells are apparent; these include the risk of 
transmitting infectious agents with the cells, high labora-
tory costs and the risk, although probably small, of malig-
nant transformation of long term cultured cells [27–29].
Alternative approaches to bone marrow processing 
for enrichment of vital progenitor cells have also been 
taken. Thus concentrated autologous bone marrow aspi-
rate was implanted together with a scaffold consisting of 
hydroxyapatite into bone defects and reportedly lead to a 
significant bone healing in almost all cases [30]. Of note, 
although clearly fulfilling the criteria of an advanced 
Fig. 4 Radiological controls (X-ray) of three representative patients preoperatively, 1–12 weeks after surgery. Red arrows show sites of fracture dur-
ing observation time
Table 3 Antibodies used for  characterization of  putative 
stem/progenitor cell populations within the BMC prepara-
tion
Antigen Conjugation Company Catalog# Clone
CD34 FITC BD-Biosciences 555820 581
CD45 PerCP BD-Biosciences 340665 2D1
CD133 PE Miltenyi biotech 130-080-801 AC133
CD271 APC Miltenyi biotech 130-091-884 ME20.4-1.H4
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therapy medicinal product (ATMP) and hence requiring 
a manufacturing authorization and some kind of market-
ing authorization, these cell products were not regulator-
approved at that time.
In humans the expected rate of secondary dislocations 
after angle-stable fixation of proximal humerus fractures 
with bone defects has been reported in the literature to 
range between 20 and 30% [10, 31]. These data are in 
agreement with the observed outcomes in our routine 
clinical practice [31].
In our presented clinical phase I study the absence of 
secondary dislocations suggests a beneficial effect of the 
BMC on bone healing and provided the rationale for a 
recently initiated placebo controlled, 1:1 randomized 
phase II clinical trial (Eudra-CT-No.: 2015-001820-51, 
ClinicalTrials.gov Identifier: NCT02803177). The advan-
tage of our approach, if proven clinically effective, are 
the almost immediate availability of the BMC, permit-
ting definitive surgical management of the fracture, the 
simplicity, and hence affordability, of drug generation, its 
carefully controlled properties.
Seeding of BMC on scaffolds in situ
Our clinical protocol restricts the BMC application to 
a single step in  situ seeding procedure on to the freshly 
implanted β-TCP scaffold due to complex regulatory con-
siderations. In a recent study we evaluated whether a sur-
face coating of the β-TCP scaffold used also in the present 
study, would enhance BMC adhesion. A three step seed-
ing procedure of BMC was applied and the seeding effi-
cacy was 95% regardless of the surface coating. Further 
analysis revealed that the seeding procedure is not associ-
ated with a cell type specific enrichment or depletion of 
putative hematopoietic stem cells and putative MSC [14]. 
Based on those results uncoated β-TCP was used as scaf-
fold in this clinical phase-I trial. Accompanying analyses 
using residual BMC of the study participants were per-
formed to estimate the seeding efficacy using a one-step 
seeding procedure in  vitro. A mean seeding efficacy of 
59% was observed which is significantly lower compared 
to the three step seeding procedure applied in [9, 14] and 
lead probably to a reduced number of BMC on the scaf-
fold placed in the defect site. It is a matter of speculation 
that the reduction of the BMC concentration in the defect 
adversely affects the bone healing process, keeping in 
mind that evidence for a correlation between MSC con-
centration in the defect and the result of the bone healing 
process was observed [32]. On the other hand, one might 
hypothesize that the concentration of transplanted BMC 
within the defect was sufficient since all fractures healed 
within 12 weeks.
Our in  vitro analyses indicate a loss of CFU-F activ-
ity during storage. Furthermore, viability is signifi-
cantly attenuated after 72 h storage at room temperature 
whereas the frequency of progenitor cell populations 
among viable cells did not differ significantly. For that rea-
son, the shelf life of BMC2012 is limited to 48 h after iso-
lation. The decline of CFU-F with increasing storage time 
was previously reported by Gastens et al. [33]. Hence, it is 
reasonable to assume that the time between bone marrow 
Fig. 5 Assessment of maximum storage time. CFU-F assay were used 
to determine Colony-forming units-fibroblast (CFU-F). Box plots of the 
median (box: median, 25% quartile and 75% quartile). Asterisk means 
a significant decline of CFU-F (marrow stromal cells) at 72 h after 
bone marrow aspiration
Table 4 Storage lesion of the IND (ancillary studies on the IND, to determine maximum shelf life)
Parameter 24 h 48 h 72 h p values (24 vs 28 h) p values (24 vs 72 h)
Cell number [absolute values] 1.7E7 (1.9E7/7.7E6) 1.6E7 (1.7E7/1.1E7) 1.1E7 (1.6E7/1.0E7) p = 0.74, not significant p = 0.31, not significant
Cell number [% 24 h] 100 (100/100) 95 (100/77.9) 74.1 (87/64.7) p = 0.17, not significant p = 0.005, significant
Vital cells [% BMC] 98.8 (98.8/98.4) 96.9 (96.9/96.9) 92.21 (94.0/84.1) p = 0.11, not significant p = 0.043, significant
Vital cells [% 24 h] 100 (100/100) 98.0 (98.9/97.1) 94.4 (97.3/85.2) p = 0.06, trend p = 0.003, significant
CD34+ CD45+ [% BMC] 1.33 (1.95/1.13) 1.47 (1.85/1.24) 1.32 (1.36/1.15) p = 1.0, not significant p = 0.81, not significant
CD34+ CD45+ CD133+ [% BMC] 0.66 (0.75/0.04) 0.6 (0.95/0.43) 0.55 (0.65/0.5) p = 1.0, not significant p = 1.0, not significant
CD45− CD271+ [% BMC] 0.01 (0.03/0.01) 0.03 (0.03/0.03) 0.02 (0.03/0.01) 1.0, not significant 1.0, not significant
CFU-F [1.0E6 BMC] 21.0 (1.95/1.13) 3.0 (9.5/2.5) 1.0 (3.0/0.5) p = 0.1, trend p = 0.04, significant
CFU-F [% of 24 h] 100.0 (100/100) 22.0 (9.7/76.2) 3.2 (0/23.8) p = 0.04, significant p = 0.03, significant
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harvest and subsequent BMC transplantation might be 
a critical factor for future BMC-supported therapies of 
large bone defects and needs to be further addressed.
It seems that BMC constitute powerful candidate 
cell types for bone regeneration. This cell-based 
approach seems feasible in clinical settings as well: 
Cells are easy to harvest, to isolate, to character-
ize and to provide in a sufficient cell number within 
some hours. Therefore, if this cell approach could be 
applied in a human clinical setting, it would clearly 
improve the present clinical approaches, which are 
still affected by complications. Complications lead to 
additional surgeries, high morbidity and loss of work-
ing time. Hence, this present biological approach 
seems feasible, safe and viable.
Conclusions
Cell therapy with autologous BMC is safe and feasible, 
as well as probably efficacious when seeded onto β-TCP 
in situ in patients with proximal humeral fractures, thus a 
forthcoming clinical trial phase-II is needed.
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